|
|
|
|
Characteristics of antiischemic and nootropic properties of ademol in a rat model of acute brain ischemia
Khodakivs'kyĭ OA
M.I. Pirogov Vinnitsa Medical University, Ukraine
DOI: https://doi.org/10.15407/fz59.05.071

Abstract
In experiments with the rat model of acute disorder of encephalic circulation (bilateral carotid occlusion) it was found that introduction of derivate of adamantan 1-adamantiloxy-3-morfolino-2 propanol (under conventional name ademol) in the dose 2 mg/kg intraabdominal in treatment regimen (in an hour after reconstruction of insult and further 1 time every 24 hours during 21 days) was accompanied by a recovery of mnemotropic properties and is more effective than cytikolin, resulting in a decreased lethality and neurological deficiency in acute and recovery periods of insults. The data received proved the usefulness of development of ademol based cerebroprotective remedy.
Keywords:
ademol, cytikolin, acute disorder of encephaliccirculation, cerebroprotection.
References
- Buresh Ya., Bureshova O., H'yuston D. Metodiki i osnovnieeksperimenti po izucheniyumozga i povedeniya. M. : Vissh. shkola, 1991. 527 p.
- Zozulya I.S., Lisenko G.I., Latoha I.O. Suchasnii stan problemi diagnostiki, perebigu, likuvannya gostrih porushen' mozkovogo krovoobigu v poliklinichnih umovah . Ukr. med. chasopis. 2011. 1112, N 6. P.30-38.
- Kitaeva E.A., Saihunov M.V., Hasanova D.R. Neiroprotektivnaya terapiya u bol'nih s polusharnim ishemicheskim insul'tom . Kazan. med. zhurn. 2009. N 5. P.671-675.
- Korolev A.A., Suslova G.A. Dinamika vosstanovleniya bol'nih v zavisimosti ot tyazhesti nevrologicheskih narushenii v protsesse reabilitatsionnogo lecheniya . Nevrol. vestn. 2009. 151, N 2. P. 15-19.
- Levin O.S. Primenenie tsitikolina v lechenii insul' ta . Rus. med. zhurn. 2008. N 26. P.1772-1777.
- Nikonov V. V., Savitskaya I. B. Rol' antagonistovglutamatnih retseptorov (PKMerts) v lechenii povrezhdenii mozga (obzor literaturi) . Meditsina neotlozhnih sostoyanii. 2012. N 5(44). P. 36-40.
- Rekomendatsii po vedeniyu bol'nih s ishemicheskim insul'tom i tranzitornimi ishemicheskimi atakami (2008) Ispolnitel'nii komitet Evropeiskoi insul'tnoi organizatsii (ESO) i Avtorskii komitet ESO . Prakt. angiologiya. 2008. N 4. P. 9-23.
- Hodakivs'kii O.A., Stepanyuk G.I., Korotkii Yu.V., Lo zins'kii M.O. Skriningtserebroprotektornogo efektu sered novih pohidnih adamantanu v umovah eksperi mental'noi ishemii golovnogo mozku . Farmakologiya ta likar. toksikologiya. 2010. N 3 (16). P. 8-11.
- Hodakivs'kii O.A. Vpliv kursovoi eksperimental'noi terapii ademolom (spolukoyu YuK1) na dinamiku po kaznikiv kislotnoluzhnoi rivnovagi v ishemizovanomu golovnomu mozku . Visn. morfologii. 2010. 16, N 4. P.787-790.
- Hodakivs'kii O.A. Otsinka vplivu eksperimental'noi terapii ademolom na intensivnist' perebigu destruk tivnih zmin v membranah neironiv u mongol's'kih pishchanok v umovah gostroi tserebral'noi ishemii . Tam samo. 2011. 17, N 1. P. 62-65.
- Hodakivs'kii O.A. Porivnyal'na otsinka vplivu pohid nih adamantanu spoluk YuK1 ta YuK4 na aktivnist' NMDAretseptoriv . Klin. farmatsiya. 2011. 15, N 4. P.60-63.
- Chekman I.S., Gubskii Yu.I., Belenichev I.F. Dokli nicheskoe izuchenie spetsificheskoi aktivnosti po tentsial'nih neiroprotektivnih preparatov: Metod. rekomendatsii. Kiev, 2010. 81 p.
- Clark W.M., Wechsler L.R., Sabounjian L.A., SchwiderskiU.E., for the Citicoline Stroke Study Group A phase IIIrandomized efficacy trial of 2000 mg citicoline in acuteischemic stroke patients . Neurology. 2001. 57. P.1595-1602.
CrossRef
PubMed
- Clark W.M., Williams B.J., Selzer K.A. A randomizedefficacy trial of citicoline in patients with acute ischemicstroke . Stroke. 2001. 30. P.2592-2597.
CrossRef
- Davalos A., AlvarezSabin J., Castillo J. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebocontrolled study (ICTUS trial). Lancet. 2012. 380. P.349-357.
CrossRef
- Fisher M., Feuerstein G., Howells D.W., Hurn P.D., Kent Th.A., Savitz S. I., LoE.H. Update of the stroke therapy academic industry roundtable preclinicalrecommendations. Stroke. 2009. 40. P.2244-2250.
CrossRef
PubMed PubMedCentral
- Jose A. lvarezSabnn M.D.;Gustavo C., Roman M.D. Citicoline in vascular cognitive impairment and vasculardementia after stroke . Ibid. 2011. 42. P. S40-S43.
- Kidwell C.S., Liebeskind D.S., Starkman S. Trends in acute schemic stroke trials through the 20th century . Ibid. 2001. 32 (6). P. 1349-1359.
- McGrow C.P. Experimental cerebral infarction effects of pentobarbital in mongolian gerbils . Arch. Neurol. 1977. 34, N 6. P.334-336.
CrossRef
- Meloni B.P., Zhu H., Knuckey N.W. Magnesium neuroprotective following global and focalcerebralischaemia? A review of publishedstudies . Magnes. Res. 2006. 19(2). P. 123-137.
PubMed
- Pandya R.S., Mao L.,Zhou H. Centralnervous system agentsfor ischemic stroke: Neuroprotectionmechanisms . Med. Chem. 2011. 1, N 27. P. 56-59.
- Saver J., Wilterdink J. Choline precursors in acute andsubacutestroke: a metaanalysis . Stroke. 2002. 33. P.353.
- Shibuta S., Varathan S., Mashimo T. Ketamine and thiopentalsodium: individual and combined neuroprotective effects on cortical cultures exposed to NMDA or nitric oxide . Brit. J. Anaesth. 2006. 97, N 4. P.517-524.
CrossRef
PubMed
|
|
|
|
|
|
|